

August 30, 2014

Creoptix AG announces the launch of its WAVE system: when high-sensitivity meets label-free

Creoptix AG announces the launch of Creoptix™ WAVE , a system for the high-sensitive label-free analysis of molecular interactions. The WAVE system addresses the needs of pharmaceutical and life science researchers looking for highest sensitivity in their real-time measurements of affinity, kinetics and concentration data.

Whether it is between a new drug candidate and its drug target or proteins in a signaling cascade, molecular interactions play a decisive role in nearly all biological and medical aspects. The understanding and analysis of molecular interactions is therefore of utmost importance in today's life science, medical and pharmaceutical research and development. The increasing demand of high accurate data and novel applications, such as fragment-based drug discovery or development of biologics, require instruments with sensitivities superior than existing technologies at improved robustness and reliability.

With the Creoptix™ WAVE a new system is now launched which takes advantage of the intrinsically most sensitive opto-physical principle for the analysis of molecular interactions, the waveguide-based interferometry. Though waveguide-based interferometry and its advantages are known since decades, its implementation into a broadly applicable instrument has not been achieved so far. Based on Creoptix' patented technology, it now is the first time that waveguide-based interferometry becomes available as a versatile, automatized and easy-to-use while highly performant instrument of outstanding sensitivity. With the WAVE system, Creoptix furthermore introduces a clever disposable sensor chip with fully integrated microfluidics. The microfluidics can hence easily be replaced by the user in case of clogging or damage by aggressive reagents. This saves precious time and costs and eliminates the dependence on external service support.

Creoptix™ WAVE is designed for all kind of label-free interaction measurements, such as for generating kinetic, affinity, specificity or concentration data. Due to its performance and high resolution at even low signal levels it is especially addressing applications with a need for high sensitivity, such as analysing very small molecules like in fragment based drug screening, or when low concentrations are required to save precious reagents or to avoid avidity effects in antibody studies.

Creoptix™ WAVE is supported by intuitive software enabling experimental set-up, real-time observation and data evaluation in one program. Raw data are available in an easily exportable xml-format, compatible with standard data handling and warehouse softwares.

To request further information about Creoptix™ WAVE, please feel free to contact us by e-mail at info@creoptix.com or phone: +41 44 533 26 60.

About Creoptix AG

Creoptix AG is a privately-held company focused on the development of next generation instruments for the high-sensitivity analysis of label-free molecular interactions based on a innovative, proprietary technology.

Creoptix' instruments are characterized by very high sensitivity while still being robust and customer-friendly. The main applications for its instruments are in the drug discovery industry and for life-science and materials research.

Creoptix was founded in 2009.

Creoptix AG, Einsiedlerstrasse 34, 8820 Wädenswil, Switzerland